Drugs / Sanhuangjingshimingwan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04486963 | Jul 2020 → Nov 2022 | age-related macular degeneration | Tasly Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sanhuangjingshimingwan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04486963 ↗ |